ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,871Medicare Part D Prescriptions Filled, Including Refills

Rank: 149 out of 2094

$510K Total Retail Price of All Prescriptions

Rank: 480 out of 2094

243 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
77% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Jersey
Lower avg

Schedule Two
Controlled Substances

17% of this provider’s 243 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 10,354 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 32%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $78 among peers.

Prescriptions per Patient

45 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Jersey
TRAZODONE HCL 451 419 1 72
LEVOTHYROXINE SODIUM 446 441 2 3
FUROSEMIDE 404 394 3 6
OMEPRAZOLE 403 402 4 4
METOPROLOL TARTRATE 369 361 5 10
CITALOPRAM HBR 333 303 6 47
SIMVASTATIN 312 291 7 1
TRAMADOL HCL 302 289 8 33
MIRTAZAPINE 291 276 9 43
WARFARIN SODIUM 271 260 10 11
POTASSIUM CHLORIDE 220 219 11 24
POLYETHYLENE GLYCOL 3350 217 206 12 75
AMLODIPINE BESYLATE 215 201 13 2
GABAPENTIN 204 191 14 23
FAMOTIDINE 179 170 15 34
CARVEDILOL 176 175 16 19
NAMENDA 157 150 17 32
RISPERIDONE 150 142 18 56
CLOZAPINE 144 113 19 212
LACTULOSE 141 138 20 65
LISINOPRIL 133 131 21 7
METOPROLOL SUCCINATE 129 120 22 9
METFORMIN HCL 128 119 23 8
LATANOPROST 117 117 24 153
DONEPEZIL HCL 112 112 25 20
BUSPIRONE HCL 102 102 26 159
HYDRALAZINE HCL 100 100 27 89
LOSARTAN POTASSIUM 94 94 28 17
ALBUTEROL SULFATE 91 86 29 90
CYMBALTA 87 85 30 61
ISOSORBIDE MONONITRATE ER 86 80 31 57
TAMSULOSIN HCL 82 74 32 29
LEVETIRACETAM 82 82 32 78
DIGOXIN 72 71 34 51
LANTUS 67 62 35 66
HUMALOG 65 56 36 164
PRAVASTATIN SODIUM 65 64 36 18
PREDNISONE 63 55 38 54
CLOPIDOGREL 61 61 39 22
LIDODERM 58 58 40 59
TRAVATAN Z 57 57 41 189
RESTASIS 55 55 42 251
ATENOLOL 54 54 43 21
OLANZAPINE 54 46 43 113
ALENDRONATE SODIUM 53 53 45 30
ADVAIR DISKUS 53 45 45 36
CARBIDOPA-LEVODOPA 52 52 47 102
KLOR-CON M10 51 51 48 190
CLONIDINE HCL 50 50 49 62
ATORVASTATIN CALCIUM 50 50 49 5
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 1, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.